Please assess the completion status of the following clinical trial:

Trial Title: Effectiveness of the Association Artesunate and Mefloquine in the Treatment of Malaria by Plasmodium Falciparum

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Be aged between 6 months and 70 years old;~* Be with mono-infection confirmed laboratorial by P.falciparum;~* Having parasite count between 250/µl and 100000/µl;~* If female, not pregnant, confirmed by specific test;~* Being feverish or report having had fever (axillary temperature \>37.5°C or 99,5°F) in last 48 hours;~* Be able to receive oral medication;~* Demonstrate interest and facility to meet the schedule of visits and monitoring for 42 days;~* Agree to participate in the study by signature (or parents) of Consent Term;~* Do not show evidence of severe malnutrition: underweight 60% of the weight-standard, below-average height for age indicating malnutrition in the past and weight-height below the average indicating dietary current deficiencies (WHO, 2006);~* Do not show danger signals to severe malaria. Note: We will be careful to include individuals who have used quinine or quinidine recently (three days before), because the risk of toxicity due to interaction with mefloquine.~Exclusion Criteria:~* Present after inclusion, danger signs/symptoms for severe malaria as recommended by the WHO;~* Present after inclusion, laboratory evidence of mixed infection with another species of Plasmodium;~* Having a diagnosis of other acute infectious disease that courses with fever, such as acute respiratory infection, common viruses of childhood diarrhea, etc;~* Having a diagnosis of chronic co morbidities or severe disease such as cirrhosis, chronic renal failure or heart failure;~* Have a history of hypersensitivity to the components of the combination ASMQ.

- Gender: ALL
- Minimum Age: 6 Months
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- artesunate & mefloquine combination (Type: EXPERIMENTAL): ASMQ will be administered to individuals with uncomplicated malaria by P. falciparum according to the dose regimen for age and weight, standardized (Farmanguinhos, Ministry of Health). For patients in the range of 5 to \<18kg (6 months to 5 years old), will be offered treatment in the pediatric presentation of Artesunate+Mefloquine 25 +50 mg (5 to \<9 kg = 1 tablet once daily for 3 days, 9 to \<18 kg = 2 tablets once daily for 3 days). To study subject aged 18 or more kilos (six years or more years old) will be given the combination of Artesunate + Mefloquine presentation ASMQ 100 +200 mg (18 to 29 kg = 1 tablet once daily for 3 days, 30 kg or more = 2 tablets once daily for 3 days). Clinically and biochemically monitoring will be done for 42 days.

Based on this trial design, predict the completion outcome and termination type (if applicable).